139 related articles for article (PubMed ID: 25292241)
1. [On the brink of a new era in the treatment of chronic hepatitis C virus infection in Denmark].
Eiset AH; Holm MP; Leutscher PD
Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292241
[TBL] [Abstract][Full Text] [Related]
2. [Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
Einecke D
MMW Fortschr Med; 2014 Feb; 156(3):26-7. PubMed ID: 24938054
[No Abstract] [Full Text] [Related]
3. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
4. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
Sethi N; Tapper EB; Vong A; Sethi S; Rourke M; Afdhal NH
J Viral Hepat; 2015 Dec; 22(12):974-6. PubMed ID: 26010946
[TBL] [Abstract][Full Text] [Related]
5. [Is more expensive always better?].
Drenth JP
Ned Tijdschr Geneeskd; 2014; 159():A8556. PubMed ID: 25534272
[TBL] [Abstract][Full Text] [Related]
6. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
Zeuzem S; Dusheiko GM; Salupere R; Mangia A; Flisiak R; Hyland RH; Illeperuma A; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Weiland O; Reesink HW; Ferenci P; Hézode C; Esteban R;
N Engl J Med; 2014 May; 370(21):1993-2001. PubMed ID: 24795201
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir as backbone of interferon free treatments.
Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
[TBL] [Abstract][Full Text] [Related]
10. Special report: cost-effectiveness studies of new hepatitis C treatments.
Mark DH;
Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
[No Abstract] [Full Text] [Related]
11. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.
Gellad ZF; Reed SD; Muir AJ
Antivir Ther; 2012; 17(6 Pt B):1189-99. PubMed ID: 23186646
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
13. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Hill A; Khoo S; Fortunak J; Simmons B; Ford N
Clin Infect Dis; 2014 Apr; 58(7):928-36. PubMed ID: 24399087
[TBL] [Abstract][Full Text] [Related]
14. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
[No Abstract] [Full Text] [Related]
15. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
D'Ambrosio R; Aghemo A; Colombo M
Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.
Krüger K; Krauth C; Rossol S; Mauss S; Boeker KHW; Müller T; Klinker H; Pathil A; Heyne R; Stahmeyer JT;
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):230-240. PubMed ID: 30325794
[TBL] [Abstract][Full Text] [Related]
18. Future of hepatitis C therapy: development of direct-acting antivirals.
Dore GJ; Matthews GV; Rockstroh J
Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
[TBL] [Abstract][Full Text] [Related]
19. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
[TBL] [Abstract][Full Text] [Related]
20. Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
Peter J; Nelson DR
Liver Int; 2015 Jan; 35 Suppl 1():65-70. PubMed ID: 25529089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]